COMP <GO>
A vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Agilent Technologies Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: A 5
— ABBV 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: A
LAST: $181.15 (-0.18%) • MKT CAP: $51.07B
balance-sheet
6.50
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (A VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | A | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.40% | 70.20% | -17.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.30% | 29.00% | -13.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.4x | 33.3x | -4.90 | A | /valuation <GO> |
| Free Cash Flow Yield | 2.26% | 3.47% | -1.21 | ABBV | /fcf-yield <GO> |
| Operating Margin | 21.30% | 24.60% | -3.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 18.80% | 6.90% | +11.90 | A | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 8.60% | -1.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 2.27% | -1.72 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 6.50 | 5.33 | +1.17 | A | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | A | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.9 | 65.1 | -3.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.5x | 113.1x | -76.60 | A | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $51.07B | $513.86B | -$462.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | A REV | ABBV REV | A GROSS % | ABBV GROSS % | A FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.95B | $61.16B | 52.4% | 70.2% | $1.15B | $17.82B |
| FY 2024 | $6.51B | $56.33B | 54.3% | 70.0% | $1.37B | $17.83B |
| FY 2023 | $6.83B | $54.32B | — | — | $1.46B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
A // BETA 0.91
ABBV // BETA 1.15